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ABSTRACT 
Objective: To evaluate the antitumour activity of meso-zeaxanthin and enumerate the mechanism of action. 
Methods: In vitro cytotoxicity was determined using transformed cells such as Dalton’s lymphoma ascites tumour cells, Ehrlich ascites tumour cells, 
L929 cells as well as using normal cells. Tumour reduction was determined by ascites tumour formation and solid tumour reduction. Mechanism of 
tumour reduction was determined by inhibition of apoptosis as seen by morphology, DNA ladder fraction and induction of P53 and caspase gene 
and inhibition of BCl2 gene. 
Results: Carotenoid meso-zeaxanthin was found to be toxic to Dalton’s Lymphoma ascites cells, Ehrlich ascites tumour cells and L929 cells (IC50, 46, 
51 and 37 μg/ml respectively) and was not cytotoxic to normal cells. Meso-zeaxanthin increased the lifespan of animals bearing Ehrlich ascites 
tumour (69.9%) and decreased the solid tumour induced by Dalton’s Lymphoma ascites tumour. Meso-zeaxanthin was found to induce apoptosis to 
DLA cells as seen from DNA Lymphoma ascites tumour. Meso-zeaxanthin was found to induce apoptosis to DLA cells as seen from DNA 
fragmentation, and DNA laddering and up regulation of P [53] and caspase 3 and 9 down regulation of BCl2 gene expression. 
Conclusion: Meso-zeaxanthin which is non-toxic was found to reduce animal tumours. 
Keywords: Meso-zeaxanthin, Antitumour activity, Apoptosis, P[53] gene-BCl2 gene 
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INTRODUCTION 
Carotenoids are phytochemicals belonging to the category of 
tetraterpenoids, which are naturally occurring in a number of fruits 
and vegetables. Carotenoids have unique chemical and physical 
properties that allow them to serve many functions in different 
organisms. A number of experimental studies have reported that β-
carotene and other carotenoids are able to inhibit the growth of 
several cancer cells, including breast cancer, colon cancer, prostate 
cancer, lung cancer, melanoma, and leukaemia cells [1, 2].  
Meso-Zeaxanthin is a xanthophyll carotenoid, having a chemical 
formula C40H56O2. Meso-Zeaxanthin [(3R,3’S)-zeaxanthin, MZ], 
(3R,3’R,6’R)-lutein and (3R,3’R)-zeaxanthin are the macular 
carotenoids present in the fovea centralis of primates retina [3]. 
These macular carotenoids protect the persons from age-related 
macular degeneration (AMD) by functioning as antioxidants and/or 
optical filters. Epidemiological studies indicated that high intake of 
lutein/zeaxanthin could reduce the risk of a variety of cancers 
including lung, liver and colon cancer. Meso-zeaxanthin has been 
reported to be non-toxic [4]. Chemopreventive effects of these oxy 
carotenoids in animals have been already reported although the 
molecular mechanisms of lutein and zeaxanthin have not been 
studied well yet. Emerging studies suggest the potential use of lutein 
and zeaxanthin in the prevention of heart disease and stroke [5]. 
Recent studies indicated that zeaxanthin is able to induce apoptosis 
in human uveal melanoma cells through Bcl-2 family proteins and 
intrinsic apoptosis pathway [6]. Our previous studies have shown 
that MZ synthesised from marigold flower extract has profound 
antioxidant activity both in vitro and in vivo [7]. MZ also exhibited 
significant antimutagenic [8], anticarcinogenic [9], radioprotective 
[10] and chemoprotective properties [11]. In the present, study we 
have checked cytotoxic and antitumour activity of MZ as well as the 
apoptosis-inducing property of MZ in tumour cell lines of murine 
origin and its possible mechanism of action. 
MATERIALS AND METHODS 
Chemicals 
Meso-zeaxanthin used in this study was supplied by Omni Active 
Health Technologies, Mumbai, Rose well Park Memorial Institute 
medium(RPMI-1640), Dulbecco’s Modified Eagle’s Medium (DMEM), 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT), ethidium bromide and oligonucleotide primer sequences for 
mouse Bcl-2, Caspase-3, Caspase-9, p53 and GAPDH were purchased 
from Sigma-Aldrich Inc. Foetal Calf Serum (FCS) was bought from 
Biological Industries, Kibbutz, Israel. Trypan blue, haematoxylin and 
eosin were obtained from E-Merck, Germany. Cell-to-cDNATM II Kit 
was purchased from Ambion Inc, Texas, and USA. 
Drug preparation  
MZ was dissolved in tetrahydrofuran (THF) for cell culture studies. 
For animal studies, 5% suspension of MZ in sunflower oil was used. 
The drug was stored in dark bottles at 4 oC to prevent oxidation. THF 
was found to be non-toxic to cells at the concentrations studied. 
Cell lines 
Dalton’s Lymphoma Ascites (DLA) and Ehrlich Ascites Carcinoma 
(EAC) cell lines were initially procured from Adayar Cancer Institute, 
Chennai and propagated as transplantable tumours in Swiss albino 
mice by injecting a suspension of cells (1x106cells/ml) 
intraperitoneally. The cells were aspired from the peritoneal cavity 
of the mouse on the 15th day for further studies. L929 (mouse lung 
fibroblast) cell line and Vero cells (monkey kidney cells) were 
purchased from National Centre for Cell Sciences (NCCS), Pune. 
Animals 
Swiss albino mice (male, 6-8 w old, weighing 22-25g) were 
purchased from Small Animal Breeding Station, Kerala Agricultural 
University, Thrissur, Kerala, India. They were housed in well-
ventilated cages with controlled conditions of light and humidity. 
They were provided with normal mouse chow (Sai Durga Food and 
Feeds, Bangalore, India) and water ad libitum. All the animal 
experiments were performed as per the instructions prescribed by 
the Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Ministry of Environment and 
Forest, Government of India, and implemented through the 
Institutional Animal Ethical Committee of the Research Centre (No. 
ACRC/IAEC-7/01-(1) on 17/5/2011). 
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Determination of in vitro cytotoxic activity of MZ towards DLA 
and EAC cells 
Short term cytotoxic activity of MZ was done by determining the 
percentage of viability of Daltons Lymphoma Ascites (DLA) and 
Ehrlich’s Ascites Carcinoma (EAC) cells using trypan blue dye 
exclusion method [12]. EAC and DLA cells aspired from the 
peritoneal cavity of mouse and washed with PBS (0.2 M, pH 7.4) and 
centrifuged at 3000 RPM for 15 min.  
The pellet was re-suspended in PBS and the process was repeated 3 
times. Finally, the cells were suspended in a known quantity of PBS 
and the cell count was adjusted to 1x107cells/ml. 100 µl of this 
diluted cell suspension was distributed into test tubes and incubated 
with different concentration of MZ (1 to 200 µg/ml) for 3 h at 37 °C. 
After 3 h the trypan blue dye exclusion test was performed to 
determine the percentage of viable cells and IC50 value was 
calculated. 
Analysis of the effect of MZ on normal spleen cells, bone marrow 
cells and peripheral blood lymphocytes by trypan blue dye exclusion 
method. 
Preparation of spleen cells  
All the procedures were done under sterile condition. Mice were 
sacrificed and an incision was made on the left side just below the 
rib and spleen was removed without any adherent tissue. The spleen 
was cut into small pieces and teased out over a stainless steel mesh 
in cold PBS. Clumps were allowed to settle in a centrifuge tube and 
kept in ice bath for 2 min. The supernatant was collected, washed 
three times with PBS and re-suspended as 107 cells/ml RPMI-1640 
medium.  
Preparation of bone marrow cells 
All the procedures were done under sterile conditions. Mice were 
sacrificed by cervical dislocation and fixed on a board stretching 
forelegs and hind legs. Skin and flesh are overlying the limbs were 
removed and femur was exposed. The shaft of the femur was 
separated from both ends and bone marrow was flushed out of the 
cavity by passing a jet of PBS with 10% FCS through the ends of the 
shaft using a 26G needle and syringe. The flushed bone marrow was 
made into a single cell suspension by repeated pipetting. It was then 
centrifuged and suspended at required cell concentrations 
(1x107cells) in PBS with 10% FCS. 
Isolation of peripheral blood lymphocytes  
Peripheral blood lymphocytes were isolated from human blood by 
Ficol-Hypaque gradient centrifugation method [13]. For this study, 
human blood was collected from the vein and diluted with PBS (1:3). 
3 ml of Ficol-Hypaque solution was taken in a clean centrifuge tube 
and the diluted blood was slowly layered over the Ficol-Hypaque 
solution. It was then centrifuged at 1500 rpm for 20 min at room 
temperature. The slight yellow coloured solution (which contains 
the lymphocyte) found in the middle of the centrifuge tube was 
carefully collected using a Pasteur pipette and washed three times 
using PBS to remove the Ficol-Hypaque solution. 
One million normal cells-spleen cells, bone marrow cells and human 
peripheral blood lymphocytes in 100 µl were incubated with and 
without different concentrations of MZ (1 to 200 µg/ml) for 3 h at 37 
°C. After 3 h, the cytotoxicity of MZ to these normal cells was 
analysed by trypan blue dye exclusion method. 
Determination of in vitro cytotoxicity of MZ towards L929 cells 
by MTT assay 
Cytotoxicity of MZ to L929 and Vero was determined by MTT assay. 
L929 and Vero cells (5000 cells/well) were seeded in 96 well flat-
bottom titre plates. After 24 h of incubation at 37 °C in 5% CO2 
atmosphere, different concentrations of MZ (1 to125 µg/ml) were 
added and further incubated for 48 h. 20 µl of MTT (5 mg/ml) was 
added 4 h before the completion of incubation [14, 15]. The plates 
were centrifuged and the supernatant was removed and then 100 µl 
of DMSO was added and the intensity of the blue colour formed was 
read at 570 nm using ELISA plate reader. 
Determination of anti-tumour activity of MZ on ascites tumour 
bearing animals 
Ascites tumour was induced by injecting EAC cells (1x106 cells/ 
animal) in the peritoneal cavity of Swiss albino mice. Thirty-six 
animals were divided into six groups (6 animals/ group). Animals in 
Group I was treated with EAC cells alone. Animals in Group II were 
treated with sunflower oil along with EAC cells (vehicle control). 
Animals in Groups III, IV and V received MZ 50, 100 and 250 mg/kg 
b. wt respectively along with EAC cells. Animals in Group VI received 
cyclophosphamide (10 mg/kg b. wt) along with EAC cells. MZ 
administration was started 24 h after tumour inoculation and 
continued for 10 consecutive days. The death of the animals due to 
tumour burden was noted every day and the percentage of increase 
in lifespan (% ILS) was calculated using the formula [(T-C)/C] x 100, 
where ‘T’ and ‘C’ are the mean survival days of treated and control 
animals respectively [16]. 
Determination of anti-tumour activity of MZ on solid tumour  
Thirty-six Swiss albino mice were divided into six groups (6 
animals/ group). Animals in Group I received DLA cells alone. Group 
II animals were treated with DLA cells and sunflower oil (vehicle 
control). Animals in Groups III, IV and V received MZ 50, 100 and 
250 mg/kg b. wt respectively along with DLA cells. Group VI animals 
received Cyclophosphamide (10 mg/kg b. wt) and DLA cells. Dalton’s 
Lymphoma Ascites (DLA) cells (1x106cells/animal) were injected 
subcutaneously on the right hind limb of mice. Twenty-four hours 
after tumour inoculation, different doses of MZ were given orally 
and continued for 10 consecutive days. Initial diameter of the hind 
limb was measured using vernier callipers. The tumour diameter 
was measured from 7th day and continued on every 3rd day. It was 
recorded up to 31 d. The tumour volume was calculated using the 
formula V= 4/3  (r12 x r2), where r1 and r2 represent the radii of the 
tumour at two different planes.  
Determination of apoptosis inducing property of MZ in DLA 
cells 
Morphological analysis  
To detect the morphological changes during apoptosis, 2×106DLA 
cells were incubated in DMEM with 10% FCS in the presence and 
absence of different concentrations of MZ (10, 20 and 25 μg/ml) at 
37 °C in 5% CO2 atmosphere for 48 h. After incubation, the cells were 
washed twice with PBS (pH 7.4) and centrifuged at 1000rpm for 15 
min. The cell button was collected and smears were made. The 
smears were then stained using haematoxylin and eosin. The cells 
were observed under a microscope (100X) and photographs were 
taken.  
DNA fragmentation assay 
Two million DLA cells were treated with different concentrations of 
MZ as described in the previous experiment. After incubation, DNA 
was extracted using phenol: chloroform: isoamyl alcohol method. 
DNA samples were separated by electrophoresis in 1.5% agarose gel 
containing ethidium bromide. DNA fragmentation was visualised 
and recorded using the gel documentation system (Vilber Lourmat, 
France).  
Determination of the effect of MZ on gene expression  
Gene expression study was carried out by the reverse transcription-
polymerase chain reaction (RT-PCR) method. Cells to cDNATMII kit 
were used for producing cDNA from DLA cells without isolating 
mRNA. DLA cells (1x106 cells/well) were seeded in 96 well ‘U’ 
bottom titre plate using DMEM with and without MZ (25 μg/ml) and 
incubated for 4 h at 37 °C in 5% CO2 atmosphere. After incubation, 
the medium was removed and the cells were washed with ice-cold 
PBS. Ice cold cell lysis buffer (100 µl) was added to the cells and 
immediately transferred to a water bath. It was incubated for 15 min 
at 75 °C and transferred to nuclease-free microcentrifuge tubes. To 
this 2 µl of Dnase-1 was added and incubated for 15 min at 37oC. 
Dnase was inactivated by heating at 75 °C for 5 min. cDNA was 
prepared from the cell lysate using cells to cDNATM II kit. Anti-
apoptotic Bcl-2 gene and pro-apoptotic genes like caspase-3, 
caspase-9 and p53 were amplified by using specific primers by RT-
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PCR (reverse transcriptase polymerised chain reaction). 
Housekeeping gene GAPDH (glyceraldehydes-3-phosphate 
dehydrogenase) was used as an internal control. Amplified PCR 
products were subjected to electrophoresis on 1.8 % agarose gel and 
analysed using gel documentation system. 
Statistical analysis 
Values are expressed as mean±standard deviation. The mean values 
use statistically analysed by one way. The values were expressed as 
mean±standard deviation (SD), n=6. The mean values were 
statistically analysed by one-way analysis of variance (ANOVA) 
followed by appropriate post hoc test (Dunnett’s multiple 
comparison test) using Graph pad Instant 3 Software. 
RESULTS 
Cytotoxicity of MZ towards DLA and EAC cells 
MZ was found to be cytotoxic towards DLA and EAC cells. 
Cytotoxicity (100%) was attained at a concentration of 125µg/ml for 
DLA cells and 150µg/ml for EAC cells. IC50 value of MZ for DLA cells 
was 46µg/ml and for EAC cells was 51µg/ml (fig. 1).  
 
Fig. 1: Cytotoxicity of meso-zeaxanthin to normal and 
transformed cell lines 
 
Effect of MZ on normal cells 
MZ did not show cytotoxicity towards normal cells like bone marrow 
cells, spleen cells, human peripheral lymphocytes and Vero cells up 
to a concentration 200 µg/ml (fig. 1).  
Cytotoxicity of MZ towards L929 cells in culture 
MZ showed a dose-dependent cytotoxic effect towards L929 cells 
during MTT assay. It showed 100% cytotoxicity to L929 cells at 
concentration 110 µg/ml (fig. 1). IC50 value was found to be 37µg/ml. 
Anti-tumour activity of MZ 
a) Ascites tumour 
Animals of the ascites tumour control group survived only for a 
period of 15.8±0.81days.  
Treatment of MZ at different concentrations increased the average 
life span of tumour bearing animals. MZ treatment at concentrations 
50, 100 and 250 mg/kg b. wt increased the survival rate of animals to 
24.88±3.5, 26.75±2.2 and 28.88±1.2 d respectively (table 1). The 
increase in the lifespan of ascites tumour bearing mice was 83% after 
250 mg/kg b. wt of MZ treatment. Standard anti-neoplastic drug 
(cyclophosphamide) treated a group of animals survived 26.63±1.6 d. 
b) Solid tumour  
A significant reduction of the solid tumour was found in MZ-treated 
groups when compared with the control group animals from 16th 
day of tumour inoculation. Tumour volume of control animals was 
3.83 cm3 on 31st day while that of 250 mg/kg b. wt MZ-treated 
animals was only 0.593 cm3 on the same day. There were also 
significant decreases in tumour volume of animals treated with 50 
and100 mg/kg b. wt of MZ (fig. 2). 
Induction of apoptosis by MZ-morphology and laddering 
Morphological analysis demonstrated that MZ was able to induce 
programmed cell death or apoptosis in DLA cells. Morphological 
changes indicating apoptosis (membrane blebbing, chromatin 
condensation, vacuole formation, DNA fragmentation and 
appearance of apoptotic bodies) [17] were observed in 10, 20 and 
25 μg/ml of MZ-treated DLA by nuclear staining [fig. 3(a)].  
Untreated DLA cells were characterised by less eosinophilic 
cytoplasm, a nucleus with a uniform distribution of chromatin 
material and absence of any morphological modification. MZ did not 
produce any characteristic apoptotic features at lower 
concentrations such as 1, 2, 2.5 and 5μg/ml.  The result of DNA 
fragmentation assay showed that MZ-treated cells had extensive 
DNA strand breaks, thereby appeared in a ladder pattern. The DNA 
isolated from DLA cells treated with 20 μg and 25μg/ml of MZ 
showed more fragmentation (lane 4 & 5) [fig. 3 (b)]. 
Effect of MZ on the expression of apoptotic genes  
Expression of anti-apoptotic gene Bcl-2 in DLA cells was found to be 
significantly downregulated by 25μg/ml of MZ treatment when 
compared to that in the untreated control. But the expression of pro-
apoptotic genes such as p53, Caspase-3 and Caspase-9 were 
significantly up-regulated by the treatment of DLA cells with 25 
μg/ml of MZ (fig. 4). The internal control GAPDH was found to be 
expressed in all the samples. The results indicated that MZ-induced 
apoptosis in DLA cells via p53 dependent Caspase-9 mediated 
intrinsic (mitochondrial) pathway. 
DISCUSSION 
Cytotoxicity towards transformed cells is a fundamental property 
required for an anticancer agent [18]. In the present study, short-
term cytotoxicity of MZ was evaluated by trypan blue exclusion 
method. Results showed that MZ had profound cytotoxicity towards 
both DLA and EAC cells and IC50 values were 46 and 51µg/ml 
respectively. 
 
Table 1: Effect of MZ administration on the survival rate and life span of ascites tumour bearing animals 
Treatment  Mean survival days % increase in life span 
Control 15.8±0.81 - 
Vehicle Control 16±0.72ns 1.6 
EAC cells+MZ 
(50 mg/kg b. wt) 
24.88±3.5*** 58 
EAC cells+MZ 
(100 mg/kg b. wt) 
26.75±2.2*** 69.9 
EAC cells+MZ 
(250 mg/kg b. wt) 
28.88±1.2*** 83.4 
EAC cells+ 
Cyclophospamide-10 mg/kg b. wt 
(Standard) 
26.63±1.6*** 69.08 
Each value represents the mean±standard deviation (SD); n=6 ns-Not significant (p>0.05); ***p<0.001 compared with vehicle control. 
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MZ also showed cytotoxicity towards transformed mouse lung 
fibroblasts cells (L929) and IC50 value was 37µg/ml. Interestingly MZ 
did not show cytotoxicity towards normal cells like bone marrow, 
spleen and human peripheral blood lymphocytes. This indicated that 
MZ was selectively cytotoxic towards transformed cells. 
Carotenoids are well known for their cytotoxic and antitumour 
effects. In vivo tumoricidal activity of MZ was evaluated by using 
Ehrlich Ascites Carcinoma (EAC) induced ascites tumour model and 
Dalton’s Lymphoma Ascites (DLA) cells induced solid tumour model. 
EAC is referred to as an undifferentiated carcinoma. It has the high 
transplantable capability, rapid proliferation, shorter life span and 
100% malignancy. EAC resembles human tumours and are most 
sensitive to chemotherapy due to the fact that they are 
undifferentiated and that they have a rapid growth rate. Many plant 
extracts were found to be effective against EAC [19]. The present 
study revealed that MZ possessed considerable antitumour activity 
against EAC cells induced ascites tumour. MZ treatment significantly 
increased the lifespan of ascites tumour bearing animals. DLA is 
transplantable, a poorly differentiated malignant tumour cell. It 
grows in both solid and ascitic forms [20]. DLA tumorigenesis model 
in Swiss albino mice provides a convenient model system to study 
anti-tumour activity within a short time. MZ was also found to 
reduce the solid tumour induced by DLA cells.  
 
Fig. 2: Effect of meso-zeaxanthin administration on solid 
tumour reduction in mice 
 
Fig. 3: a) Morphological analysis of the cells after treatment 
with meso-zeaxanthin Indicating membrane rupture and 
apoptotic bodies, b) Formation of DNA ladder by treatment of 
DLA cells with meso-zeaxanthin 
 
The anti-tumour activity of MZ was found to be concentration 
dependent. The dose of MZ needed for tumour reduction was higher 
compared to other standard drug used for cancer chemotherapy. 
Equivalent human dosage of MZ is approximately 5-25 mg/kg i.e., for 
a 60 kg body weight person it will be 300-1500 mg/day. Dose of 
oxicarotenoids useful to prevent macular degeneration is only 10 
mg/day. Present study indicates that much higher concentration of 
oxycarotenoids is needed in order to produce tumour reduction. 
Similar results are also seen in the case of lutein [21]. MZ was found 
to be highly non-toxic to animals at this dosage. 
 
 
Fig. 4: Expression of genes related to apoptosis by treatment of DLA cells with mezzo-zeaxanthin 
 
Apoptosis (programmed cell death) is a process in which cells play 
an active role in their own death. Apoptosis is a normal component 
of the development and health of multicellular organisms. Problems 
with the regulation of apoptosis have been implicated in a number of 
diseases. Cancer is a disease that is often characterised by a 
deficiency in apoptosis. Cancer cells typically possess a number of 
mutations that have allowed them to ignore normal cellular signals 
regulating their growth and become more proliferative than normal 
cells. Under normal circumstances, damaged cells will undergo 
apoptosis. But in the case of cancer cells, mutations occurred and 
that prevent cells from undergoing apoptosis. Induction of apoptosis 
or cell cycle arrest by chemopreventive compounds can be an 
excellent approach to inhibit the promotion and progression of 
carcinogenesis and to remove genetically damaged, pre-initiated or 
neoplastic cells from the body [22]. 
Apoptosis is characterized by membrane blebbing, chromosome 
condensation, vacuole formation and formation of apoptotic bodies. 
These features can be seen in DLA cells treated with MZ. One of the 
hallmarks of apoptosis is the cleavage of chromosomal DNA into 
nucleosomal units. The fragmentation of DNA into nucleosomal units 
(multiples of 180-200 bps) is caused by an enzyme known as CAD 
(Caspase Activated DNase). Normally CAD exists as an inactive 
complex with ICAD (inhibitor of CAD). During apoptosis, ICAD is 
cleaved by caspases such as caspase 3 to release CAD leads to rapid 
fragmentation of the nuclear DNA (Inoue et al., 2005). DNA isolated 
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from DLA cells treated with MZ appeared in ladder pattern, 
confirming apoptosis induction by MZ. 
p53 is a tumour suppressor gene that acts to integrate multiple 
stress signals into a series of diverse antiproliferative responses. 
One of the most important functions of p53 is its ability to activate 
apoptosis, and disruption of this process can promote tumour 
progression and chemoresistance. Induction of p53-dependent 
apoptotic pathway found to be an attractive strategy for anti-cancer 
treatment. In the present study, MZ up-regulated the expressions of 
p53, caspase 9 and caspase 3 genes indicating that MZ can induce 
p53 dependent intrinsic apoptotic pathway. 
Apoptosis regulator Bcl-2 (B-cell leukaemia/lymphoma 2 protein) is 
a family of evolutionarily related proteins. These proteins 
govern mitochondrial outer membrane permeabilization (MOMP) 
and can be either pro-apoptotic (Bax, BAD, Bak and Bok among 
others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w 
among an assortment of others). Most cells express a variety of both 
anti-apoptotic and pro-apoptotic Bcl-2 proteins and the interaction 
within this family dictates whether a cell survives or dies. The 
dysregulation of the anti-apoptotic Bcl-2 family members is one of 
the defining features of cancer cells in comparison to normal cells, 
and this significantly contributes to the resistance of cancer cells to 
current treatment modalities. Several drugs that can inhibit Bcl-2 
and related anti-apoptotic proteins have been developed, and some 
of them show considerable promise in the clinic [23]. In this study, 
expression of Bcl-2, an anti-apoptotic gene, occurred in transformed 
DLA cells. But the expression of Bcl-2 was significantly 
downregulated by MZ treatment. The present study revealed that 
the cytotoxic and antitumour effect of MZ on transformed cells is 
mediated through p53 dependent mitochondrial apoptotic pathway. 
CONCLUSION 
Xanthophyll carotenoid, meso-zeaxanthin was found to be cytotoxic 
to tumour cells such as Dalton’s lymphoma ascites tumour cells 
(DLA) and Ehrlich ascites tumour (EAC) cells as well as L929 
fibroblasts. It was found to be nontoxic to normal cells. Meso-
zeaxanthin increased the life span of EAC tumour bearing animals 
and reduced the solid tumour induced by DLA cells in mice; meso-
Zeaxanthin was found to induce apoptosis of tumour cells as seen by 
morphological and DNA laddering. Moreover, it was found to induce 
apoptotic gene P[53]and caspase 3&9 and inhibited BCl2 gene 
indicating the mechanism of action of meso-zeaxanthin by the 
induction of apoptosis.  
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